PARIS, January 29, 2019 /PRNewswire/ --
Valneva is a leading European biotech company specialized in innovative vaccines. Thomas Lingelbach, President & CEO of Valneva, comments on the Group's strategy.
Watch video interview and read transcript: https://www.eurobusinessmedia.com/video/valneva-group-strategy?utm_source=ceo-direct&utm_medium=wire
Topics covered in the interview include:
- The Company
- Main Sources of revenue
- Clinical vaccine portofolio
- Company evolution
About Valneva SE
Valneva is a biotech company developing and commercializing vaccines for infectious diseases with major unmet needs. Valneva's portfolio includes two commercial vaccines for travelers: IXIARO®/JESPECT® indicated for the prevention of Japanese encephalitis and DUKORAL® indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by ETEC. The Company has various vaccines in development including a unique vaccine against Lyme disease. Valneva has operations in Austria, Sweden, the United Kingdom, France, Canada and the US with approximately 500 employees. More information is available at http://www.valneva.com .